Eton Pharmaceuticals, Inc.ETONEarnings & Financial Report
Nasdaq
NextMar 19, 2026
ETON Q3 2025 Key Financial Metrics
Revenue
$22.5M
Gross Profit
$7.9M
Operating Profit
$-1.4M
Net Profit
$-1.9M
Gross Margin
35.0%
Operating Margin
-6.1%
Net Margin
-8.6%
YoY Growth
117.5%
EPS
$-0.07
Financial Flow
Eton Pharmaceuticals, Inc. Q3 2025 Financial Summary
Eton Pharmaceuticals, Inc. reported revenue of $22.5M for Q3 2025, with a net profit of $-1.9M (-8.6% margin). Cost of goods sold was $14.6M, operating expenses totaled $9.2M.
Key Financial Metrics
| Total Revenue | $22.5M |
|---|---|
| Net Profit | $-1.9M |
| Gross Margin | 35.0% |
| Operating Margin | -6.1% |
| Report Period | Q3 2025 |
Eton Pharmaceuticals, Inc. Annual Revenue by Year
Eton Pharmaceuticals, Inc. annual revenue history includes year-by-year totals (for example, 2024 revenue was $39.0M).
| Year | Annual Revenue |
|---|---|
| 2024 | $39.0M |
| 2023 | $31.6M |
| 2022 | $21.3M |
Income Statement
| Q4 2023 | Q1 2024 | Q2 2024 | Q3 2024 | Q4 2024 | Q1 2025 | Q2 2025 | Q3 2025 | |
|---|---|---|---|---|---|---|---|---|
| Revenue | $7.3M | $8.0M | $9.1M | $10.3M | $11.6M | $17.3M | $18.9M | $22.5M |
| YoY Growth | -13.9% | 50.2% | -24.4% | 46.9% | 59.3% | 116.9% | 108.6% | 117.5% |
Balance Sheet
| Q4 2023 | Q1 2024 | Q2 2024 | Q3 2024 | Q4 2024 | Q1 2025 | Q2 2025 | Q3 2025 | |
|---|---|---|---|---|---|---|---|---|
| Assets | $31.7M | $30.8M | $31.8M | $35.8M | $76.1M | $84.0M | $101.7M | $104.5M |
| Liabilities | $16.3M | $15.3M | $18.4M | $19.9M | $51.7M | $59.6M | $77.7M | $81.4M |
| Equity | $15.5M | $15.5M | $13.5M | $16.0M | $24.4M | $24.4M | $24.0M | $23.1M |
Cash Flow
| Q4 2023 | Q1 2024 | Q2 2024 | Q3 2024 | Q4 2024 | Q1 2025 | Q2 2025 | Q3 2025 | |
|---|---|---|---|---|---|---|---|---|
| Operating CF | $387000 | $-2.5M | $1.3M | $3.0M | $-765000 | $2.1M | $8.0M | $12.0M |